This study wants to learn more about how a drug called L-citrulline affects lung function and asthma control in people with deployment-related asthma.
In this study we want to learn more about how common health problems like high blood pressure, vision problems, and kidney disease are in people with cystic fibrosis-related diabetes (CFRD).
The goal of this study is to compare how well the iLet Bionic Pancreas works in people with Cystic Fibrosis Related Diabetes compared to others with the same condition using their regular care.
In this study we want to standardize the type of data we collect during a treatment called embolization for people with pulmonary arteriovenous malformations (PAVMs). We will then use this data to compare other treatment methods for PAVMs and learn how they impact patient health and healing.
We are looking for asthmatics and non-asthmatics between 18-65 years old to participate in a study that will look at how cells in the lungs are different between populations.
This study wants to learn how early changes in airway cells may help predict who is at risk for developing Chronic Obstructive Pulmonary Disease (COPD). We are looking for people who are current smokers with or without COPD.
This study wants to learn more about how the right side of the heart works in people with chronic obstructive pulmonary disease (COPD). We want to see how the heart responds to high blood pressure in the lungs, both while resting and during exercise. The goal is to find patterns that could lead to better treatments for people with COPD.
The Lung PCA BU goals include enrollment of informative retrospective and prospective patients from which informative biospecimens can be collected and processed for advanced analyses of PMLs. Central to this process will be the development of techniques to optimize data production from limited tissues. The generation of a deep and interactive database will be critical to help direct the studies...
1. Determine if L-citrulline supplementation improves asthma control and increases FeNO (co-primary outcomes). Secondary outcomes will include changes in plasma L-arginine/ADMA, lung function (FEV1) and bronchial hyperreactivity. Asthmatic subjects will receive either 15 g L-citrulline/day or matched placebo for 7 weeks followed by a 4 week washout and then 7 weeks of the opposite treatment. A pa...
This study plans to learn more about pulmonary fibrosis and determine if some diseases that cause scarring in the lung might be inherited diseases. We are especially interested in the genetics of pulmonary fibrosis and cases where it might run in families. What we learn may be helpful in the future to people with pulmonary fibrosis and their family members.